Search Results - "Bergseth, Grethe"

Refine Results
  1. 1

    An international serum standard for application in assays to detect human complement activation products by Bergseth, Grethe, Ludviksen, Judith K., Kirschfink, Michael, Giclas, Patricia C., Nilsson, Bo, Mollnes, Tom E.

    Published in Molecular immunology (15-12-2013)
    “…The importance of the complement system in clinical medicine has become evident during the last decades and complement therapeutics has now reached the clinic…”
    Get full text
    Journal Article
  2. 2
  3. 3

    NHDL, a recombinant VL/VH hybrid antibody control for IgG2/4 antibodies by Lau, Corinna, McAdam, Martin Berner, Bergseth, Grethe, Grevys, Algirdas, Bruun, Jack Ansgar, Ludviksen, Judith Krey, Fure, Hilde, Espevik, Terje, Moen, Anders, Andersen, Jan Terje, Mollnes, Tom Eirik

    Published in mAbs (01-01-2020)
    “…The mechanism of action of recombinant IgG2/4 antibodies involves blocking of their target without the induction of effector functions. Examples are eculizumab…”
    Get full text
    Journal Article
  4. 4

    Artificial Surface-Induced Inflammation Relies on Complement Factor 5: Proof From a Deficient Person by Bergseth, Grethe, BS, Lambris, John D., PhD, Mollnes, Tom Eirik, MD, PhD, Lappegård, Knut Tore, MD, PhD

    Published in The Annals of thoracic surgery (01-02-2011)
    “…Background Exposing blood to artificial surfaces results in an inflammatory response, including complement activation and cytokine release. The aim of this…”
    Get full text
    Journal Article
  5. 5

    Clinical and Complement Long-Term Follow-Up of a Pediatric Patient with C3 Mutation-Related Atypical Hemolytic Uremic Syndrome by Mollnes, Tom Eirik, Bosnes, Vidar, Stokke, Arne, Ludviksen, Judith Krey, Bergseth, Grethe, Bjerre, Anna, Karpman, Diana

    Published in Case reports in nephrology (2018)
    “…We report a pediatric patient with atypical hemolytic uremic syndrome due to a C3 gain-of-function mutation diagnosed in infancy. She was treated from the…”
    Get full text
    Journal Article
  6. 6

    Effect on mother and child of eculizumab given before caesarean section in a patient with severe antiphospholipid syndrome: A case report by Gustavsen, Alice, Skattum, Lillemor, Bergseth, Grethe, Lorentzen, Bjorg, Floisand, Yngvar, Bosnes, Vidar, Mollnes, Tom Eirik, Barratt-Due, Andreas

    Published in Medicine (Baltimore) (01-03-2017)
    “…Antiphospholipid syndrome (APS) in pregnancy may trigger the life-threatening catastrophic antiphospholipid syndrome (CAPS). Complement activation is…”
    Get full text
    Journal Article
  7. 7

    Effect on mother and child of eculizumab given before caesarean section in a patient with severe antiphospholipid syndrome by Gustavsen, Alice, Skattum, Lillemor, Bergseth, Grete, Lorentzen, Bjørg, Fløisand, Yngvar, Bosnes, Vidar, Mollnes, Tom Eirik, Barratt-Due, Andreas

    Published in Medicine (Baltimore) (01-03-2017)
    “…Rationale:Antiphospholipid syndrome (APS) in pregnancy may trigger the lifethreatening catastrophic antiphospholipid syndrome (CAPS). Complement activation is…”
    Get full text
    Journal Article
  8. 8

    Platelet compatibility of an artificial surface modified with functionally active heparin by Mollnes, T E, Videm, V, Christiansen, D, Bergseth, G, Riesenfeld, J, Hovig, T

    Published in Thrombosis and haemostasis (01-09-1999)
    “…Platelet compatibility after coating an artificial material with functionally active heparin was investigated. Blood was circulated in uncoated or heparin…”
    Get more information
    Journal Article
  9. 9
  10. 10
  11. 11

    Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome by Barratt-Due, Andreas, Fløisand, Yngvar, Orrem, Hilde L, Kvam, Ann K, Holme, Pål A, Bergseth, Grethe, Tjønnfjord, Geir E, Mollnes, Tom E

    Published in Rheumatology (Oxford, England) (01-07-2016)
    “…Catastrophic antiphospholipid syndrome is associated with excessive complement activation explaining the clinical efficacy of complement inhibitory treatment…”
    Get full text
    Journal Article
  12. 12

    NHDL, a recombinant V L /V H hybrid antibody control for IgG2/4 antibodies by Lau, Corinna, McAdam, Martin Berner, Bergseth, Grethe, Grevys, Algirdas, Bruun, Jack Ansgar, Ludviksen, Judith Krey, Fure, Hilde, Espevik, Terje, Moen, Anders, Andersen, Jan Terje, Mollnes, Tom Eirik

    Published in mAbs (01-01-2020)
    “…The mechanism of action of recombinant IgG2/4 antibodies involves blocking of their target without the induction of effector functions. Examples are eculizumab…”
    Get full text
    Journal Article
  13. 13

    Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome by Volokhina, Elena B, van de Kar, Nicole C.A.J, Bergseth, Grethe, van der Velden, Thea J.A.M, Westra, Dineke, Wetzels, Jack F.M, van den Heuvel, Lambertus P, Mollnes, Tom Eirik

    Published in Clinical immunology (Orlando, Fla.) (01-10-2015)
    “…Abstract Complement C5 inhibitor eculizumab treatment in atypical hemolytic uremic syndrome is effective, but associated with high costs. Complement inhibition…”
    Get full text
    Journal Article
  14. 14

    Eculizumab-C5 complexes express a C5a neoepitope in vivo: Consequences for interpretation of patient complement analyses by Nilsson, Per H., Thomas, Anub Mathew, Bergseth, Grethe, Gustavsen, Alice, Volokhina, Elena B., van den Heuvel, Lambertus P., Barratt-Due, Andreas, Mollnes, Tom E.

    Published in Molecular immunology (01-09-2017)
    “…•Antibodies to neoepitopes are crucial tools for detection of complement activation.•Changes of complement proteins without activation can expose…”
    Get full text
    Journal Article
  15. 15

    Essential role of the C5a receptor in E coli–induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation by Mollnes, Tom Eirik, Brekke, Ole-Lars, Fung, Michael, Fure, Hilde, Christiansen, Dorte, Bergseth, Grethe, Videm, Vibeke, Lappegård, Knut Tore, Köhl, Jörg, Lambris, John D.

    Published in Blood (01-09-2002)
    “…Complement plays an essential role in inflammation and tissue damage. However, it is largely unknown to what extent the system acts as a primary inducer of…”
    Get full text
    Journal Article
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20